Diazoxide for use in the treatment of central nervous system (CNS) autoimmune demyelinating diseases

摘要

The invention relates to the use of diazoxide or a pharmaceutically acceptable salt thereof at low doses to treat a CNS autoimmune demyelinating disease selected from selected from multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM), and post-vaccinal encephalitis (PVE).